Literature DB >> 11556834

CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.

G Della Torre1, B Pasini, S Frigerio, R Donghi, D Rovini, D Delia, G Peters, T J Huot, G Bianchi-Scarra, F Lantieri, M Rodolfo, G Parmiani, M A Pierotti.   

Abstract

Physical interaction between CDKN2A/p16 and CDK4 proteins regulates the cell cycle progression through the G1 phase and dysfunction of these proteins by gene mutation is implicated in genetic predisposition to melanoma. We analysed 15 Italian melanoma families for germ line mutations in the coding region of the CDKN2A gene and exon 2 of the CDK4 gene. One novel disease-associated mutation (P48T), 3 known pathological mutations (R24P, G101W and N71S) and 2 common polymorphisms (A148T and Nt500 G>C) were identified in the CDKN2A gene. In a family harbouring the R24P mutation, an intronic variant (IVS1, +37 G>C) of uncertain significance was detected in a non-carrier melanoma case. The overall incidence of CDKN2A mutations was 33.3%, but this percentage was higher in families with 3 or more melanoma cases (50%) than in those with only 2 affected relatives (25%). Noteworthy, functional analysis established that the novel mutated protein, while being impaired in cell growth and inhibition assays, retains some in vitro binding to CDK4/6. No variant in the p16-binding region of CDK4 was identified in our families. Our results, obtained in a heterogeneous group of families, support the view that inactivating mutations of CDKN2A contribute to melanoma susceptibility more than activating mutations of CDK4 and that other genetic factors must be responsible for melanoma clustering in a high proportion of families. In addition, they indicate the need for a combination of functional assays to determine the pathogenetic nature of new CDKN2A mutations. Copyright 2001 Cancer Research Campaign http://www.bjcancer.com.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11556834      PMCID: PMC2375081          DOI: 10.1054/bjoc.2001.1991

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  28 in total

1.  Mutation screening of the CDKN2A promoter in melanoma families.

Authors:  M Harland; E A Holland; P Ghiorzo; M Mantelli; G Bianchi-Scarrà; A M Goldstein; M A Tucker; B A Ponder; G J Mann; D T Bishop; J Newton Bishop
Journal:  Genes Chromosomes Cancer       Date:  2000-05       Impact factor: 5.006

Review 2.  Genes involved in melanoma: an overview of INK4a and other loci.

Authors:  M Castellano; G Parmiani
Journal:  Melanoma Res       Date:  1999-10       Impact factor: 3.599

3.  Characterization of ligurian melanoma families and risk of occurrence of other neoplasia.

Authors:  P Ghiorzo; P Ciotti; M Mantelli; A Heouaine; P Queirolo; M L Rainero; C Ferrari; P L Santi; R De Marchi; A Farris; F Ajmar; P Bruzzi; G Bianchi-Scarrà
Journal:  Int J Cancer       Date:  1999-11-12       Impact factor: 7.396

4.  CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas.

Authors:  E A Holland; H Schmid; R F Kefford; G J Mann
Journal:  Genes Chromosomes Cancer       Date:  1999-08       Impact factor: 5.006

5.  Functional evaluation of tumour-specific variants of p16INK4a/CDKN2A: correlation with protein structure information.

Authors:  M Ruas; S Brookes; N Q McDonald; G Peters
Journal:  Oncogene       Date:  1999-09-23       Impact factor: 9.867

6.  Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.

Authors:  A M Goldstein; J P Struewing; A Chidambaram; M C Fraser; M A Tucker
Journal:  J Natl Cancer Inst       Date:  2000-06-21       Impact factor: 13.506

7.  Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group.

Authors:  N Soufir; M F Avril; A Chompret; F Demenais; J Bombled; A Spatz; D Stoppa-Lyonnet; J Bénard; B Bressac-de Paillerets
Journal:  Hum Mol Genet       Date:  1998-02       Impact factor: 6.150

8.  Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene.

Authors:  H Tsao; E Benoit; A J Sober; C Thiele; F G Haluska
Journal:  Cancer Res       Date:  1998-01-01       Impact factor: 12.701

Review 9.  The p16INK4a/CDKN2A tumor suppressor and its relatives.

Authors:  M Ruas; G Peters
Journal:  Biochim Biophys Acta       Date:  1998-10-14

10.  Crystal structure of the complex of the cyclin D-dependent kinase Cdk6 bound to the cell-cycle inhibitor p19INK4d.

Authors:  D H Brotherton; V Dhanaraj; S Wick; L Brizuela; P J Domaille; E Volyanik; X Xu; E Parisini; B O Smith; S J Archer; M Serrano; S L Brenner; T L Blundell; E D Laue
Journal:  Nature       Date:  1998-09-17       Impact factor: 49.962

View more
  12 in total

1.  Absence of germline CDKN2A mutation in Sicilian patients with familial malignant melanoma: Could it be a population-specific genetic signature?

Authors:  Sara Di Lorenzo; Daniele Fanale; Bartolo Corradino; Valentina Caló; Gaetana Rinaldi; Viviana Bazan; Antonio Giordano; Adriana Cordova; Antonio Russo
Journal:  Cancer Biol Ther       Date:  2016       Impact factor: 4.742

2.  Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.

Authors:  Miriam Potrony; Joan Anton Puig-Butillé; Paula Aguilera; Celia Badenas; Cristina Carrera; Josep Malvehy; Susana Puig
Journal:  J Am Acad Dermatol       Date:  2014-07-24       Impact factor: 11.527

Review 3.  Epidemiological and genetic factors underlying melanoma development in Italy.

Authors:  Giuseppe Palmieri; Maria Colombino; Milena Casula; Mario Budroni; Antonella Manca; Maria Cristina Sini; Amelia Lissia; Ignazio Stanganelli; Paolo A Ascierto; Antonio Cossu
Journal:  Melanoma Manag       Date:  2015-05-18

4.  Arf-dependent regulation of Pdgf signaling in perivascular cells in the developing mouse eye.

Authors:  Ricardo L A Silva; J Derek Thornton; Amy C Martin; Jerold E Rehg; David Bertwistle; Frederique Zindy; Stephen X Skapek
Journal:  EMBO J       Date:  2005-07-21       Impact factor: 11.598

5.  Assessment of functional effects of unclassified genetic variants.

Authors:  Fergus J Couch; Lene Juel Rasmussen; Robert Hofstra; Alvaro N A Monteiro; Marc S Greenblatt; Niels de Wind
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

Review 6.  Selection criteria for genetic assessment of patients with familial melanoma.

Authors:  Sancy A Leachman; John Carucci; Wendy Kohlmann; Kimberly C Banks; Maryam M Asgari; Wilma Bergman; Giovanna Bianchi-Scarrà; Teresa Brentnall; Brigitte Bressac-de Paillerets; William Bruno; Clara Curiel-Lewandrowski; Femke A de Snoo; Tadeusz Debniak; Marie-France Demierre; David Elder; Alisa M Goldstein; Jane Grant-Kels; Allan C Halpern; Christian Ingvar; Richard F Kefford; Julie Lang; Rona M MacKie; Graham J Mann; Kurt Mueller; Julia Newton-Bishop; Håkan Olsson; Gloria M Petersen; Susana Puig; Darrell Rigel; Susan M Swetter; Margaret A Tucker; Emanuel Yakobson; John A Zitelli; Hensin Tsao
Journal:  J Am Acad Dermatol       Date:  2009-10       Impact factor: 11.527

7.  CDKN2A mutations and melanoma risk in the Icelandic population.

Authors:  A M Goldstein; S N Stacey; J H Olafsson; G F Jonsson; A Helgason; P Sulem; B Sigurgeirsson; K R Benediktsdottir; K Thorisdottir; R Ragnarsson; J Kjartansson; J Kostic; G Masson; K Kristjansson; J R Gulcher; A Kong; U Thorsteinsdottir; T Rafnar; M A Tucker; K Stefansson
Journal:  J Med Genet       Date:  2008-01-04       Impact factor: 6.318

8.  Frequent p16-independent inactivation of p14ARF in human melanoma.

Authors:  Daniel E Freedberg; Sushila H Rigas; Julie Russak; Weiming Gai; Margarita Kaplow; Iman Osman; Faye Turner; Juliette A Randerson-Moor; Alan Houghton; Klaus Busam; D Timothy Bishop; Boris C Bastian; Julia A Newton-Bishop; David Polsky
Journal:  J Natl Cancer Inst       Date:  2008-05-27       Impact factor: 13.506

9.  DNA sequence and analysis of human chromosome 9.

Authors:  S J Humphray; K Oliver; A R Hunt; R W Plumb; J E Loveland; K L Howe; T D Andrews; S Searle; S E Hunt; C E Scott; M C Jones; R Ainscough; J P Almeida; K D Ambrose; R I S Ashwell; A K Babbage; S Babbage; C L Bagguley; J Bailey; R Banerjee; D J Barker; K F Barlow; K Bates; H Beasley; O Beasley; C P Bird; S Bray-Allen; A J Brown; J Y Brown; D Burford; W Burrill; J Burton; C Carder; N P Carter; J C Chapman; Y Chen; G Clarke; S Y Clark; C M Clee; S Clegg; R E Collier; N Corby; M Crosier; A T Cummings; J Davies; P Dhami; M Dunn; I Dutta; L W Dyer; M E Earthrowl; L Faulkner; C J Fleming; A Frankish; J A Frankland; L French; D G Fricker; P Garner; J Garnett; J Ghori; J G R Gilbert; C Glison; D V Grafham; S Gribble; C Griffiths; S Griffiths-Jones; R Grocock; J Guy; R E Hall; S Hammond; J L Harley; E S I Harrison; E A Hart; P D Heath; C D Henderson; B L Hopkins; P J Howard; P J Howden; E Huckle; C Johnson; D Johnson; A A Joy; M Kay; S Keenan; J K Kershaw; A M Kimberley; A King; A Knights; G K Laird; C Langford; S Lawlor; D A Leongamornlert; M Leversha; C Lloyd; D M Lloyd; J Lovell; S Martin; M Mashreghi-Mohammadi; L Matthews; S McLaren; K E McLay; A McMurray; S Milne; T Nickerson; J Nisbett; G Nordsiek; A V Pearce; A I Peck; K M Porter; R Pandian; S Pelan; B Phillimore; S Povey; Y Ramsey; V Rand; M Scharfe; H K Sehra; R Shownkeen; S K Sims; C D Skuce; M Smith; C A Steward; D Swarbreck; N Sycamore; J Tester; A Thorpe; A Tracey; A Tromans; D W Thomas; M Wall; J M Wallis; A P West; S L Whitehead; D L Willey; S A Williams; L Wilming; P W Wray; L Young; J L Ashurst; A Coulson; H Blöcker; R Durbin; J E Sulston; T Hubbard; M J Jackson; D R Bentley; S Beck; J Rogers; I Dunham
Journal:  Nature       Date:  2004-05-27       Impact factor: 49.962

10.  p16INK4a-induced senescence is disabled by melanoma-associated mutations.

Authors:  Sebastian Haferkamp; Therese M Becker; Lyndee L Scurr; Richard F Kefford; Helen Rizos
Journal:  Aging Cell       Date:  2008-10       Impact factor: 9.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.